



The Effect of Dexmedetomidine and Esmolol on Early Postoperative Cognitive Dysfunction After Middle Ear Surgery Under Hypotensive Technique: A Comparative, Randomized, Double-blind Study

Mahmoud Hussein Bahr ¹, Doaa Abu Elkassim Rashwan ¹ and Samaa A Kasem ^{1,*}

¹Department of Anesthesia, Surgical Intensive Care and Pain Management, Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt

*Corresponding author: Faculty of Medicine, Beni - Suef University, Postal Code: 62511-0020822318605, Beni - Suef, Egypt. Email: samaa.kasem@gmail.com

Received 2020 July 22; Revised 2020 September 12; Accepted 2020 October 06.

Abstract

Objectives: Postoperative cognitive dysfunction (POCD) is multifactorial, which may be caused by anesthetic and surgical causes or cerebral injury. This study aimed to evaluate the effect of dexmedetomidine as a neuroprotective drug compared to esmolol on the prevalence of POCD in adult patients undergoing middle ear surgery under hypotensive anesthesia.

Methods: This study included male and female adult patients, according to the American Society of Anesthesiology physical status (ASA) I, the patients who underwent middle ear surgeries under hypotensive anesthesia and were randomly assigned to two groups that received esmolol and dexmedetomidine. The demographic data, age, gender, mean arterial blood pressure, duration of the surgery, evaluation of the surgical field, and the Mini-Mental State Examination (MMSE) (preoperatively and at 1, 6 and 24 hours postoperatively) were recorded.

Results: There was a significant difference between the number of patients who had POCD in MMSE1: 12 cases in the esmolol group (41.37%) compared to three cases in the dexmedetomidine group (9.38%) ($P = 0.016$), in MMSE6: 10 cases in the esmolol group (34.48%) compared with two cases in the dexmedetomidine group (6.89%) ($P = 0.023$) and in MMSE24: seven cases in the esmolol group (24.13%) compared with one case in the dexmedetomidine group (3.44%) ($P = 0.022$), while the median and range of MMSE score were comparable between the two groups ($P > 0.05$).

Conclusions: This study suggests that intraoperative use of dexmedetomidine as an adjuvant to hypotensive anesthesia reduces the incidence of POCD compared to esmolol.

Keywords: Dexmedetomidine, Esmolol, Postoperative Cognitive Dysfunction, Hypotensive Anesthesia

1. Background

Cognitive dysfunction is the impairment of memory, perception of mental process, or information processing (1). Postoperative cognitive dysfunction (POCD) is multifactorial, which may be caused by anesthetic and surgical causes or cerebral injury. It may develop into permanent cognitive injury (2, 3). Controlled hypotension is elective decreasing of arterial blood pressure in a controllable manner to decrease surgical bleeding (4) by lowering the mean arterial pressure (MAP) by 30% from the baseline reading or (5) maintaining it at 50 - 65 mmHg (6). Hypotension during anesthesia is related to the pathogenesis of POCD due to the reduced perfusion to important organs, mainly the brain (7, 8). It is a challenging process for anesthetists to provide hemodynamic stability and pre-

venting early mental and cognitive dysfunction. Previous studies compared esmolol and dexmedetomidine as adjuvants during hypotensive anesthesia in terms of their ability to control the blood pressure and to optimize the surgical field (9), and to our interest, we found in previously published literature by Celebi et al. (10) that the use of esmolol to induce controlled hypotension was associated with POCD. Dexmedetomidine decreases the cerebral blood flow by reducing the cerebral perfusion pressure, but the oxygen supply to the brain is not influenced (11, 12), and it was reported to have a neuroprotective effect (13, 14), so we hypothesize that using dexmedetomidine as an adjuvant during hypotensive anesthesia may reduce the incidence of early POCD.

2. Objectives

The primary aim of this study was to evaluate the effect of dexmedetomidine, as a neuroprotective drug compared to esmolol, on the prevalence of POCD in adult patients scheduled for middle ear surgeries under controlled hypotensive technique. Furthermore, the status of the surgical field was assessed by the surgeon as the second purpose.

3. Methods

This comparative, randomized double-blinded (the surgeon and the anesthetist who collected the data were blinded to the study protocol) was conducted at Beni-Suef University Hospital after approval of the anesthesiology, surgical ICU and pain management department, and the local ethics and research committee (approval NO.FMBSUREC/0532019/Bahr, date of approval 5 March 2019) and obtaining written informed consents from the patients from April 2019 to January 2020. It was registered at ClinicalTrials.gov (ClinicalTrials.gov ID: NCT03854417) and included 58 male and female patients in the age group between 20 - 50 years, according to the American Society of Anesthesiology physical status (ASA) I. The patients of both groups were educated (secondary school or higher), literate, educated patients and patients with less than high school degrees were excluded. Patients with known allergy to the drugs used in the study or drug abuse, contraindication to hypotensive anesthesia, and pregnant females were excluded. Routine preoperative assessment was performed, including history, physical examination, hematological and biochemical testing were obtained, and the procedure was explained to the patient.

Mini-Mental State Examination (MMSE) (Appendix 1 in Supplementary File) was used to evaluate the cognitive function because it is an easily applicable, reliable test and the most commonly used composite measure. It was performed preoperatively by an anesthesiologist (blinded to the study protocol and skilled in using the test), a score of 30 points was considered maximum, and the patients were excluded from this study if the preoperative score is less than 24 (15, 16). All patients received premedication 60 minutes before surgery (ondansetron 4 mg I.V.). Upon admission to the operating theater, the monitors were applied, and the operating room temperature was adjusted at 22°C, and normothermia was maintained using warm IV fluid and a forced-air warming blanket. Under the aseptic technique and after performing the Allens test, the radial

artery was cannulated for direct blood pressure recording. Anesthesia was induced using propofol, fentanyl (2 µg/kg), and atracurium and maintained by sevoflurane 2% in an oxygen air mixture and atracurium infusion. The patients were mechanically ventilated to maintain normocarbia. The patients were randomly divided using sealed envelop technique as follow:

- Esmolol group [n = 29]: received bolus of esmolol (Esmolol Hydrochloride, Baxter CO) 100 µg/kg over 30 seconds then continuous infusion of 7 µg/kg/h (5).
- Dexmedetomidine group [n = 29] received dexmedetomidine (Perceptin, Pfizer CO), 1 µg/kg/h over 10 minutes then 0.7 µg/kg/h (17).

Esmolol and dexmedetomidine infusion were titrated according to the target blood pressure (MAP 60 - 65 mmHg). The rescue treatment of bradycardia (heart rate less than 60) or hypotension (MAP less than 60 mmHg) was to continue infusion of esmolol and dexmedetomidine and administer ephedrine in 5 mg increments if the MAP decreased to 55 mmHg or less, and 0.5 mg i.v. atropine for the patients who developed bradycardia (heart rate < 60 beats/minute), and to exclude those patients from the study, but none of the patients had profound hypotension or bradycardia. At the end of surgery; infusing the study drugs was ceased, the inhalation of sevoflurane was discontinued, and the neuromuscular blockade was antagonized, the patients were extubated while fully conscious, obeying commands, and transferred to the recovery room for close monitoring and when the post-anesthesia modified Aldert score (18) was 7 or more the patient was considered awake to confirm that all patients had similar post-anesthesia recovery state before evaluating the cognitive function. The patients were discharged from the post-anesthesia recovery unit to the ward when the score \geq 9 (phase I recovery).

The following data were recorded by an anesthesiologist blinded to the study: demographic data (age, weight, gender), heart rate (beat/min), mean arterial blood pressure (mmHg) were recorded before the induction of anesthesia, and every 15 min, duration of the surgery, the surgical field was evaluated by the surgeon [at the start, middle, and end of the surgery and the results were averaged] using a 5-point bleeding scale (5), MMSE was also applied preoperatively, and after an hour, this reading was considered (MMSE1), and the test was repeated at 6 hours (MMSE6) and 24 hours (MMSE24) postoperatively (15, 16).

3.1. Statistical Analysis

The sample size was calculated using student t-test and G*Power software version 3.1.2 for MS Windows, Germany. For the comparison of the occurrence of early POCD between groups of controlled hypotension during middle ear surgeries (16). The calculated minimum sample size was 23 patients in each arm/group at an α of 0.05 and power of 80%. Twenty-nine patients were included in each group, the data were presented as mean \pm standard deviation, median, and range or number and percentage. Numerical data were tested for normal distribution using the Kolmogorov-Smirnov test. Student t-test was used for independent samples, and the chi-square test was used to compare the categorical data. A P-value less than 0.05 was statistically considered significant. The data were analyzed by using SPSS software.

4. Results

The patients completed the study, as indicated in figure 1. The demographic characteristics (age, weight, gender), and duration of the surgery were not statistically different between both groups (Table 1). The patients of both groups were educated (secondary school or higher). The socio-economic level was also comparable. The median and range of the bleeding score were 1 (0-3) and 2 (1-4) for esmolol and dexmedetomidine groups, respectively, with highly statistically significant differences ($P < 0.005$). The median and range of MMSE score were comparable between the two groups preoperatively and at 1, 6 and 24 hours postoperatively ($P > 0.05$), (Table 3) but since a decrease of 2 or more of MMSE was considered cognitive dysfunction and the score lower than 24 was recorded as cognitive impairment. Based on this knowledge, we calculated the incidence of POCD at 1, 6, 24 hours postoperatively as number and percentages. The incidence of POCD was less in the dexmedetomidine group at 1, 6 and 24 hours postoperatively compared to the esmolol group ($P < 0.05$) (Table 3). The MAP and heart rates were comparable between both groups without a statistically significant difference (Figures 2 and 3, respectively). None of the patients developed bradycardia or profound hypotension. Moreover, no side effects related to dexmedetomidine were reported (e.g., delayed recovery or sedation).

5. Discussion

This study demonstrated that the use of dexmedetomidine as an adjuvant for hypotensive anesthesia during

middle ear surgery for adult patients was associated with a decreased incidence of POCD compared to esmolol.

The fluctuation of the systemic blood pressure, cardiac output or cerebral metabolic rate, and the use of drugs with vasoconstrictor effect may influence the cerebral perfusion and metabolism (19). Clinicians thought that cognitive dysfunction is more frequent with general anesthesia (19) because the drugs used for general anesthesia may antagonize the central cholinergic transmission and decrease the acetylcholine in the brain, which is crucial for memory and learning (20). It has been reported that POCD is caused by hypotension and excessive doses of anesthetic drugs (19, 20). POCD may be related to postoperative pain (7), inflammatory or metabolic stresses or endocrine stress response related to surgery (10), prolonged duration of anesthesia, less catheterization or postoperative infection (1).

Several reports on animal models reported that dexmedetomidine has neuroprotective effects (21-24). Recent evidence suggested that its effect is regulated by the binding to α_2 -adrenoceptors, which are regulators of cell survival (25, 26). Yang et al. (27) meta-analysis reported that perioperative dexmedetomidine treatment significantly reduced the incidence of POCD, this was also reported by Zhang et al. (28) in elderly patients scheduled for laparoscopic surgery for colorectal cancer. Also, Zhou et al. (29) meta-analysis showed improvement of postoperative MMSE score in elderly patients when using dexmedetomidine. Chen et al. (30) reported a reduced incidence of POCD by 9.20% and 21.31% in dexmedetomidine and control groups, respectively.

On the other hand, Mohamed and Shaaban reported that using dexmedetomidine was not associated with protection against POCD in elderly patients after major surgery (31), another study also reported that dexmedetomidine has no neuroprotective effect after cardiac surgery, and both attributed their results to small sample size, long duration of surgery and type of patient (32). When using esmolol and dexmedetomidine to reach the target MAP (55 - 65 mmHg), it was not required to increase the sevoflurane concentration, and this was the benefit of using these adjuvants during controlled hypotension since increasing the dose of inhalational anesthetics to produce controlled hypotensive anesthesia affects the brain function, including the cerebral blood flow and metabolism. Also, fentanyl 2 μ g/kg was administered during the induction of anesthesia, and mild to moderate painful surgery makes the change in sevoflurane level mild (2% - 2.5%).




Figure 1. CONSORT flow diagram of this study.

Table 1. Demographic Data of the Patients and Duration of Surgery^a

	Esmolol Group, (n = 29)	Dexmedetomidine Group, (n = 29)	P-Value
Age (years), mean ± SD	33.1 ± 7.3	31.9 ± 8.1	0.552
Weight (kg), mean ± SD	78.7 ± 12.7	79.2 ± 12.2	0.883
Gender, No. (%)			0.793
Males	15 (51.7)	14 (48.3)	
Females	14 (48.3)	15 (51.7)	
Duration of surgery (min), mean ± SD	69.8 ± 11.4	69.1 ± 11.6	0.820

^aP-value < 0.05 is statistically significant, P-value < 0.01 is highly significant.

Table 2. Mini-Mental State Examination(MMSE) Score^a

	Esmolol Group, (n = 29)	Dexmedetomidine Group, (n = 29)	P-Value
MMSE preoperative	27 (24 - 30)	27 (24 - 30)	0.880
MMSE 1h post	26 (23 - 30)	27 (23 - 30)	0.263
MMSE 6h post	27 (24 - 30)	27 (24 - 30)	0.385
MMSE 24h post	28 (24 - 30)	28 (24 - 30)	0.658

^aData are described in median (range); P-value < 0.05 is statistically significant.

Table 3. The Number and Percentage of Patients Who Had Post-Operative Cognitive Dysfunction (MMSE 23 - 24)^a

	Esmolol Group, (n = 29)	Dexmedetomidine Group, (n = 29)	P-Value
1 h Postoperative	12 (41.37)	3 (10.34)	0.016
6 h Postoperative	10 (34.48)	2 (6.89)	0.002
24 h Postoperative	7 (24.13)	1 (3.44)	0.022

^aValues are described as number (%); P-value < 0.05 is statistically significant.




Figure 2. Mean and SD of [mean blood pressure (mmHg)] between the study groups, [Dex: dexmedetomidine].




Figure 3. Mean and SD of [heart rates HR (beats/min)] between the study groups, [Dex: dexmedetomidine].

5.1. Conclusion

This study suggested that intraoperative use of dexmedetomidine as an adjuvant to hypotensive anesthesia in middle age patients after middle ear surgery reduced the incidence of POCD compared to esmolol. Further studies are recommended on a larger population of different age groups to prove the role of dexmedetomidine in protection against POCD with different anesthetic techniques and to follow up the patients postoperatively.

Supplementary Material

Supplementary material(s) is available [here](#) [To read supplementary materials, please refer to the journal website and open PDF/HTML].

Acknowledgments

We would like to acknowledge Asharaf Abel Mawgood and Ahmed Badawy for the final revision and their valuable comments.

Footnotes

Authors' Contribution: Mahmood Hussein Bahr designed the protocol and carried out the clinical part, writing, and revision of the article; Doaa You Elkassim Rashwan collected the patients, revising the manuscript; Samaa A.kasim revised the statistical analysis, collecting the background research and writing the article; The authors read and approved the final manuscript.

Registration Code: ClinicalTrials.gov (ClinicalTrials.gov/2019/03/201903890002).

Conflict of Interest: No potential conflict of interest related to this article was reported.

Ethical Approval: The study was performed in compliance with the Helsinki Declaration after approval of the Research Ethical Committee of Beni-Suef University Hospitals.

Funding/Support: The authors received no financial supports.

Informed Consent: Written informed consent was obtained from all patients.

References

1. Hanning CD. Postoperative cognitive dysfunction. *Br J Anaesth.* 2005;**95**(1):82-7. doi: [10.1093/bja/aei062](#). [PubMed: [15640305](#)].

2. Monk TG, Weldon BC, Garvan CW, Dede DE, van der Aa MT, Heilman KM, et al. Predictors of cognitive dysfunction after major noncardiac surgery. *Anesthesiology.* 2008;**108**(1):18-30. doi: [10.1097/O1.anes.0000296071.19434.1e](#). [PubMed: [18156878](#)].
3. Canet J, Raeder J, Rasmussen LS, Enlund M, Kuipers HM, Hanning CD, et al. Cognitive dysfunction after minor surgery in the elderly. *Acta Anaesthesiol Scand.* 2003;**47**(10):1204-10. doi: [10.1046/j.1399-6576.2003.00238.x](#). [PubMed: [14616316](#)].
4. Morgan GE, Mikhail MS, Murray MJ. Hypotensive anesthesia. Morgan & Mikhail's clinical anesthesiology. New Delhi, India: Taylor & Francis; 2012. p. 255-62.
5. Guney A, Kaya FN, Yavascaoglu B, Gurbet A, Selmi N, et al. Comparison of esmolol to nitroglycerin on controlled hypotension during nasal surgery. *Eurasian J Med Biol.* 2012;**44**(2):99-102. doi: [10.5152/eajm.2012.23](#). [PubMed: [20212323](#)]. [PubMed Central: [PMC4261293](#)].
6. Degoute CS. Controlled hypotension: a guide to drug choice. *Drugs.* 2007;**67**(7):1057-66. doi: [10.2165/000034957000767070-00007](#). [PubMed: [17440000](#)].
7. Moller JT, Clusmann P, Rasmussen LS, Rasmussen H, Canet J, et al. Long-term postoperative cognitive dysfunction in the elderly: ISPO2 study. *Thromb Haemostas.* 1998;**351**(9106):857-61. doi: [10.1016/s0140-6736\(97\)07382-0](#). [PubMed: [9266923](#)].
8. Shak M, Yoav L, Abu-Elraj I. Hypotensive anesthesia versus normotensive anesthesia during major maxillofacial surgery: a meta-analysis of the literature. *ScientificWorldJournal.* 2015;**2015**:480728. doi: [10.1155/2015/480728](#). [PubMed: [25811042](#)]. [PubMed Central: [PMC4542211](#)].
9. Das A, Chhauha S, Bhattacharya S, Basunia SR, Mitra T, Halder PS, et al. Controlled hypotension in day care functional endoscopic sinus surgery: A comparison between esmolol and dexmedetomidine: A prospective, double-blind, and randomized study. *Saudi J Anaesth.* 2016;**10**(3):276-82. doi: [10.4103/1658-354X.174919](#). [PubMed: [27375381](#)]. [PubMed Central: [PMC4916810](#)].
10. Celebi N, Artukoglu F, Dal D, Saricaoglu F, Celiker V, Aypar U. Effect of hypotensive anesthesia on cognitive functions. A comparison of esmolol and remifentanyl during tympanoplasty. *Saudi Med J.* 2007;**28**(9):1357-61. [PubMed: [17768460](#)].
11. Sharma S, Suthar OP, Tak ML, Thanvi A, Paliwal N, Karnawat R. Comparison of esmolol and dexmedetomidine for suppression of hemodynamic response to laryngoscopy and endotracheal intubation in adult patients undergoing elective general surgery: A prospective, randomized controlled double-blinded study. *Anesth Essays Res.* 2018;**12**(1):262-6. doi: [10.4103/aer.AER_226_17](#). [PubMed: [29628593](#)]. [PubMed Central: [PMC5872877](#)].
12. Ma D, Rajakumaraswamy N, Maze M. alpha2-Adrenoceptor agonists: shedding light on neuroprotection? *Br Med Bull.* 2004;**71**:77-92. doi: [10.1093/bmb/ldh036](#). [PubMed: [15684247](#)].
13. Safavynia SA, Goldstein PA. The role of neuroinflammation in postoperative cognitive dysfunction: Moving from hypothesis to treatment. *Front Psychiatry.* 2018;**9**:752. doi: [10.3389/fpsy.2018.00752](#). [PubMed: [30705643](#)]. [PubMed Central: [PMC6345198](#)].
14. Sato K, Kimura T, Nishikawa T, Tobe Y, Masaki Y. Neuroprotective effects of a combination of dexmedetomidine and hypothermia after incomplete cerebral ischemia in rats. *Acta Anaesthesiol Scand.* 2010;**54**(3):377-82. doi: [10.1111/j.1399-6576.2009.02139.x](#). [PubMed: [19860751](#)].
15. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state for the clinician. *J Psychiat Res.* 1975;**12**(3):189-98. doi: [10.1016/0022-3956\(75\)90026-6](#).

16. Niazi AA. Postoperative cognitive function and controlled hypotensive anesthesia in patients undergoing septoplasty. *Egypt J Anaesth*. 2019;**32**(1):61-6. doi: [10.1016/j.egja.2015.10.002](https://doi.org/10.1016/j.egja.2015.10.002).
17. American Society of Anesthesiologists Task Force on Sedation and Analgesia by Non-Anesthesiologists. Practice guidelines for sedation and analgesia by non-anesthesiologists. *Anesthesiology*. 2002;**96**(4):1004-17. doi: [10.1097/00000542-200204000-00031](https://doi.org/10.1097/00000542-200204000-00031). [PubMed: [11964611](https://pubmed.ncbi.nlm.nih.gov/11964611/)].
18. Aldrete J. The post-anesthesia recovery score revisited. *J Clin Anesth*. 1995;**7**(1):89-91. doi: [10.1016/0952-8180\(94\)00001-k](https://doi.org/10.1016/0952-8180(94)00001-k).
19. Williams-Russo P, Sharrock NE, Mattis S, Sztatowski TP, Charlson ME. Cognitive effects after epidural vs general anesthesia in older adults. A randomized trial. *JAMA*. 1995;**274**(1):44-50. [PubMed: [7791257](https://pubmed.ncbi.nlm.nih.gov/7791257/)].
20. Jungwirth B, Zieglgansberger W, Kochs E, Rammes G. Anesthesia and postoperative cognitive dysfunction (POCD). *Mini Rev Med Chem*. 2009;**9**(14):1568-79. doi: [10.2174/138955709791012229](https://doi.org/10.2174/138955709791012229). [PubMed: [20088778](https://pubmed.ncbi.nlm.nih.gov/20088778/)].
21. Sanders RD, Xu J, Shu Y, Januszewski A, Halder S, Fidalgo A, et al. Dexmedetomidine attenuates isoflurane-induced neurocognitive impairment in neonatal rats. *Anesthesiology*. 2009;**110**(5):1077-85. doi: [10.1097/ALN.0b013e31819daedd](https://doi.org/10.1097/ALN.0b013e31819daedd). [PubMed: [19352168](https://pubmed.ncbi.nlm.nih.gov/19352168/)].
22. Goyagi T, Nishikawa T, Tobe Y, Masaki Y. The combined neuroprotective effects of lidocaine and dexmedetomidine after transient forebrain ischemia in rats. *Acta Anaesthesiol Scand*. 2009;**53**(9):1176-83. doi: [10.1111/j.1399-6576.2009.01976.x](https://doi.org/10.1111/j.1399-6576.2009.01976.x). [PubMed: [19388884](https://pubmed.ncbi.nlm.nih.gov/19388884/)].
23. Kuhmonen J, Haapalinna A, Sivenius J. Effects of dexmedetomidine after transient and permanent occlusion of the middle cerebral artery in the rat. *J Neural Transm (Vienna)*. 2001;**108**(3):261-71. doi: [10.1007/s007020170071](https://doi.org/10.1007/s007020170071). [PubMed: [11341477](https://pubmed.ncbi.nlm.nih.gov/11341477/)].
24. Kuhmonen J, Pokorny J, Miettinen R, Haapalinna A, Jolkonen J, Riekkinen PS, et al. Neuroprotective effects of dexmedetomidine in the gerbil hippocampus after transient global ischemia. *Anesthesiology*. 1997;**87**(2):371-7. doi: [10.1097/00000542-199708000-00023](https://doi.org/10.1097/00000542-199708000-00023). [PubMed: [9286902](https://pubmed.ncbi.nlm.nih.gov/9286902/)].
25. Dahmani S, Paris A, Jannier V, Rouelle C, Rouelle C, Rouelle J, et al. Dexmedetomidine increases hippocampal phospho-ERK1/2 extracellular signal-regulated protein kinase and cAMP content in alpha-2-adrenoceptor-independent mechanism: evidence for the involvement of imidazoline II receptors. *Anesthesiology*. 2008;**108**(3):457-66. doi: [10.1097/ALN.0b013e318164ca81](https://doi.org/10.1097/ALN.0b013e318164ca81). [PubMed: [18292683](https://pubmed.ncbi.nlm.nih.gov/18292683/)].
26. Shen J, Wu Y, Xu JY, Zhang J, Sinclair SH, Yanoff M, et al. ERK- and Akt-dependent neuroprotection by erythropoietin (EPO) against glyoxal-AGEs via modulation of Bcl-xL, Bax, and BAD. *Invest Ophthalmol Vis Sci*. 2010;**51**(1):35-46. doi: [10.1167/iovs.09-3544](https://doi.org/10.1167/iovs.09-3544). [PubMed: [19670448](https://pubmed.ncbi.nlm.nih.gov/19670448/)].
27. Yang W, Kong LS, Zhu XX, Wang RX, Liu Y, Chen LR. Effect of dexmedetomidine on postoperative cognitive dysfunction and inflammation in patients after general anaesthesia: A PRISMA-compliant systematic review and meta-analysis. *Medicine (Baltimore)*. 2019;**98**(18):e15383. doi: [10.1097/MD.00000000000015383](https://doi.org/10.1097/MD.00000000000015383). [PubMed: [31070488](https://pubmed.ncbi.nlm.nih.gov/31070488/)]. [PubMed Central: [PMC6504304](https://pubmed.ncbi.nlm.nih.gov/PMC6504304/)].
28. Zhang Y, Xing Z, Xu Y, Xu S. Effects of different doses of dexmedetomidine on cognitive dysfunction in elderly patients after laparoscopic surgery for colorectal cancer. *Int J Med Res*. 2016;**43**(1):1-6. doi: [10.1177/03000605166671623](https://doi.org/10.1177/03000605166671623). [PubMed: [27133743](https://pubmed.ncbi.nlm.nih.gov/27133743/)]. [PubMed Central: [PMC5536774](https://pubmed.ncbi.nlm.nih.gov/PMC5536774/)].
29. Zhou C, Zhu Y, Li H, Qian L. Effect of dexmedetomidine on postoperative cognitive dysfunction in elderly patients after general anaesthesia: A meta-analysis. *J Int Med Res*. 2016;**44**(6):1182-90. doi: [10.1177/03000605166671623](https://doi.org/10.1177/03000605166671623). [PubMed: [27913743](https://pubmed.ncbi.nlm.nih.gov/27913743/)]. [PubMed Central: [PMC5536774](https://pubmed.ncbi.nlm.nih.gov/PMC5536774/)].
30. Chen H, Liu B, Zhang F, Xue Y, Li X, Lei W. The effects of dexmedetomidine on post-operative cognitive dysfunction and inflammatory factors in elderly patients. *Int J Clin Exp Med*. 2015;**8**(3):4601-5. [PubMed: [26064322](https://pubmed.ncbi.nlm.nih.gov/26064322/)]. [PubMed Central: [PMC4443226](https://pubmed.ncbi.nlm.nih.gov/PMC4443226/)].
31. Mohamed Elmaghrabi AR. The effect of Dexmedetomidine on the incidence of postoperative cognitive dysfunction in elderly patients after laparoscopic and abdominal surgery. *Egypt J Anaesth*. 2019;**30**(4):331-8. doi: [10.1016/j.egja.2014.03.007](https://doi.org/10.1016/j.egja.2014.03.007).
32. Gulemanji DS, Donmez A, Aldemir D, Sezgin A, Turkoglu S. Dexmedetomidine during coronary artery bypass grafting surgery: is it neuroprotective?—A preliminary study. *Acta Anaesthesiol Scand*. 2007;**51**(8):1093-8. doi: [10.1111/j.1399-6576.2007.01377.x](https://doi.org/10.1111/j.1399-6576.2007.01377.x). [PubMed: [17697305](https://pubmed.ncbi.nlm.nih.gov/17697305/)].